Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | CAMARGO, Leandro do Nascimento | |
dc.contributor.author | RIGHETTI, Renato Fraga | |
dc.contributor.author | ARISTOTELES, Luciana Ritha de Cassia Rolim Barbosa | |
dc.contributor.author | SANTOS, Tabata Maruyama dos | |
dc.contributor.author | SOUZA, Flavia Castro Ribas de | |
dc.contributor.author | FUKUZAKI, Silvia | |
dc.contributor.author | CRUZ, Maysa Mariana | |
dc.contributor.author | ALONSO-VALE, Maria Isabel Cardoso | |
dc.contributor.author | SARAIVA-ROMANHOLO, Beatriz Mangueira | |
dc.contributor.author | PRADO, Carla Maximo | |
dc.contributor.author | MARTINS, Milton de Arruda | |
dc.contributor.author | LEICK, Aparecida | |
dc.contributor.author | TIBERIO, Iolanda de Fatima Lopes Calvo | |
dc.date.accessioned | 2018-02-02T16:53:24Z | |
dc.date.available | 2018-02-02T16:53:24Z | |
dc.date.issued | 2018 | |
dc.description.abstract | Inflammation plays a central role in the development of asthma, which is considered an allergic disease with a classic Th2 inflammatory profile. However, cytokine IL-17 has been examined to better understand the pathophysiology of this disease. Severe asthmatic patients experience frequent exacerbations, leading to infection, and subsequently show altered levels of inflammation that are unlikely to be due to the Th2 immune response alone. This study estimates the effects of anti-IL-17 therapy in the pulmonary parenchyma in a murine asthma model exacerbated by LPS. BALB/c mice were sensitized with intraperitoneal ovalbumin and repeatedly exposed to inhalation with ovalbumin, followed by treatment with or without anti-IL-17. Twenty-four hours prior to the end of the 29-day experimental protocol, the two groups received LPS (0.1 mg/ml intratracheal OVA-LPS and OVA-LPS IL-17). We subsequently evaluated bronchoalveolar lavage fluid, performed a lung tissue morphometric analysis, and measured IL-6 gene expression. OVA-LPS-treated animals treated with anti-IL-17 showed decreased pulmonary inflammation, edema, oxidative stress, and extracellular matrix remodeling compared to the non-treated OVA and OVA-LPS groups (p < 0.05). The anti-IL-17 treatment also decreased the numbers of dendritic cells, FOXP3, NF-kappa B, and Rho kinase 1-and 2-positive cells compared to the non-treated OVA and OVA-LPS groups (p < 0.05). In conclusion, these data suggest that inhibition of IL-17 is a promising therapeutic avenue, even in exacerbated asthmatic patients, and significantly contributes to the control of Th1/Th2/Th17 inflammation, chemokine expression, extracellular matrix remodeling, and oxidative stress in a murine experimental asthma model exacerbated by LPS. | |
dc.description.index | PubMed | |
dc.description.sponsorship | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/17944-1] | |
dc.description.sponsorship | National Council of Scientific and the Technological Development (CNPq) | |
dc.description.sponsorship | Laboratory of Medical Investigations (LIM-20 FMUSP) | |
dc.identifier.citation | FRONTIERS IN IMMUNOLOGY, v.8, article ID 1835, 14p, 2018 | |
dc.identifier.doi | 10.3389/fimmu.2017.01835 | |
dc.identifier.issn | 1664-3224 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/24894 | |
dc.language.iso | eng | |
dc.publisher | FRONTIERS MEDIA SA | |
dc.relation.ispartof | Frontiers in Immunology | |
dc.rights | openAccess | |
dc.rights.holder | Copyright FRONTIERS MEDIA SA | |
dc.subject | anti-IL-17 | |
dc.subject | distal lung | |
dc.subject | asthma | |
dc.subject | inflammation | |
dc.subject | LPS-exacerbated | |
dc.subject.other | allergic pulmonary inflammation | |
dc.subject.other | rho-kinase inhibition | |
dc.subject.other | lung-tissue mechanics | |
dc.subject.other | factor-kappa-b | |
dc.subject.other | airway inflammation | |
dc.subject.other | t-cells | |
dc.subject.other | oral tolerance | |
dc.subject.other | smooth-muscle | |
dc.subject.other | guinea-pigs | |
dc.subject.other | th17 cells | |
dc.subject.wos | Immunology | |
dc.title | Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS | |
dc.type | article | |
dc.type.category | original article | |
dc.type.version | publishedVersion | |
dspace.entity.type | Publication | |
hcfmusp.author.external | CRUZ, Maysa Mariana:Univ Fed Sao Paulo, Inst Biomed Sci, Dept Biol Sci, Sao Paulo, Brazil | |
hcfmusp.author.external | ALONSO-VALE, Maria Isabel Cardoso:Univ Fed Sao Paulo, Inst Biomed Sci, Dept Biol Sci, Sao Paulo, Brazil | |
hcfmusp.author.external | PRADO, Carla Maximo:Univ Fed Sao Paulo, Dept Biol Sci, Sao Paulo, Brazil | |
hcfmusp.contributor.author-fmusphc | LEANDRO DO NASCIMENTO CAMARGO | |
hcfmusp.contributor.author-fmusphc | RENATO FRAGA RIGHETTI | |
hcfmusp.contributor.author-fmusphc | LUCIANA RITHA DE CASSIA ROLIM BARBOSA ARISTOTELES | |
hcfmusp.contributor.author-fmusphc | TABATA MARUYAMA DOS SANTOS | |
hcfmusp.contributor.author-fmusphc | FLAVIA CASTRO RIBAS DE SOUZA | |
hcfmusp.contributor.author-fmusphc | SILVIA FUKUZAKI | |
hcfmusp.contributor.author-fmusphc | BEATRIZ MANGUEIRA SARAIVA RAMANHOLO | |
hcfmusp.contributor.author-fmusphc | MILTON DE ARRUDA MARTINS | |
hcfmusp.contributor.author-fmusphc | EDNA APARECIDA LEICK | |
hcfmusp.contributor.author-fmusphc | IOLANDA DE FATIMA LOPES CALVO TIBERIO | |
hcfmusp.description.articlenumber | 1835 | |
hcfmusp.description.volume | 8 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.pubmed | 29379497 | |
hcfmusp.origem.wos | WOS:000419371800001 | |
hcfmusp.publisher.city | LAUSANNE | |
hcfmusp.publisher.country | SWITZERLAND | |
hcfmusp.relation.reference | Abdelmageed ME, 2016, CAN J PHYSIOL PHARM, V94, P140, DOI 10.1139/cjpp-2015-0219 | |
hcfmusp.relation.reference | Al-Muhsen S, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-34 | |
hcfmusp.relation.reference | Angeli P, 2008, AM J PHYSIOL-LUNG C, V294, pL1197, DOI 10.1152/ajplung.00199.2007 | |
hcfmusp.relation.reference | Arantes-Costa FM, 2008, TOXICOL PATHOL, V36, P680, DOI 10.1177/0192623308317427 | |
hcfmusp.relation.reference | Aristoteles LRCRB, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-52 | |
hcfmusp.relation.reference | Bae JS, 2017, ALLERGY ASTHMA IMMUN, V9, P169 | |
hcfmusp.relation.reference | Barlow JL, 2011, CLIN EXP ALLERGY, V41, P1447, DOI 10.1111/j.1365-2222.2011.03806.x | |
hcfmusp.relation.reference | Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC | |
hcfmusp.relation.reference | Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557 | |
hcfmusp.relation.reference | Ckless K, 2007, AM J RESP CELL MOL, V36, P645, DOI 10.1165/rcmb.2006-0329SM | |
hcfmusp.relation.reference | Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026 | |
hcfmusp.relation.reference | Dolhnikoff M, 2009, J ALLERGY CLIN IMMUN, V123, P1090, DOI 10.1016/j.jaci.2009.02.032 | |
hcfmusp.relation.reference | Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x | |
hcfmusp.relation.reference | Durrant DM, 2010, IMMUNOL INVEST, V39, P526, DOI 10.3109/08820131003615498 | |
hcfmusp.relation.reference | Fajt ML, 2017, ALLERGY ASTHMA IMMUN, V9, P3, DOI 10.4168/aair.2017.9.1.3 | |
hcfmusp.relation.reference | Fodor RS, 2015, ROM J MORPHOL EMBRYO, V56, P1329 | |
hcfmusp.relation.reference | Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204 | |
hcfmusp.relation.reference | GINA, 2015, GLOB STRAT ASTHM MAN | |
hcfmusp.relation.reference | Gosens R, 2004, EUR J PHARMACOL, V494, P73, DOI 10.1016/j.ejphar.2004.04.035 | |
hcfmusp.relation.reference | He WX, 2012, J ENDODONT, V38, P464, DOI 10.1016/j.joen.2011.12.021 | |
hcfmusp.relation.reference | Ingram JL, 2015, METALLOPROTEINASES M, V2, P61, DOI [10.2147/MNM.S63614, DOI 10.2147/MNM.S63614] | |
hcfmusp.relation.reference | Kiss T, 2016, BRIT J ANAESTH, V116, P708, DOI 10.1093/bja/aew093 | |
hcfmusp.relation.reference | Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710 | |
hcfmusp.relation.reference | Krishnan A, 2012, LAB INVEST, V92, P1712, DOI 10.1038/labinvest.2012.121 | |
hcfmusp.relation.reference | Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684 | |
hcfmusp.relation.reference | Lowe APP, 2015, BRIT J PHARMACOL, V172, P2588, DOI 10.1111/bph.13080 | |
hcfmusp.relation.reference | MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391 | |
hcfmusp.relation.reference | Mauad T, 2008, REV PANAM SALUD PUBL, V23, P418, DOI 10.1590/S1020-49892008000600007 | |
hcfmusp.relation.reference | Menden HL, 2016, AM J RESP CELL MOL, V55, P767, DOI 10.1165/rcmb.2016-0006OC | |
hcfmusp.relation.reference | Murakami D, 2007, CLIN EXP ALLERGY, V37, P339, DOI 10.1111/j.1365-2222.2006.02633.x | |
hcfmusp.relation.reference | Nakashima AS, 2008, J APPL PHYSIOL, V104, P1778, DOI 10.1152/japplphysiol.00830.2007 | |
hcfmusp.relation.reference | Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002 | |
hcfmusp.relation.reference | Oshita Y, 2003, THORAX, V58, P757, DOI 10.1136/thorax.58.9.757 | |
hcfmusp.relation.reference | Overbeek SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055612 | |
hcfmusp.relation.reference | Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031 | |
hcfmusp.relation.reference | Pantano C, 2008, AM J RESP CRIT CARE, V177, P959, DOI [10.1164/rccm.200707-1096OC, 10.1164/rccm.200707-10960C] | |
hcfmusp.relation.reference | Sakoda CPP, 2016, ACTA HISTOCHEM, V118, P615, DOI 10.1016/j.acthis.2016.07.001 | |
hcfmusp.relation.reference | Petroni RC, 2015, INFLAMMATION, V38, P2026, DOI 10.1007/s10753-015-0183-4 | |
hcfmusp.relation.reference | Pigati PA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0073-4 | |
hcfmusp.relation.reference | Pinheiro NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120441 | |
hcfmusp.relation.reference | Possa SS, 2012, AM J PHYSIOL-LUNG C, V303, pL939, DOI 10.1152/ajplung.00034.2012 | |
hcfmusp.relation.reference | Prado CM, 2011, EXP LUNG RES, V37, P259, DOI 10.3109/01902148.2010.538289 | |
hcfmusp.relation.reference | Pyzik M, 2007, J LEUKOCYTE BIOL, V82, P335, DOI 10.1189/jlb.1006644 | |
hcfmusp.relation.reference | Qin XJ, 2012, ALLERGY, V67, P1547, DOI 10.1111/all.12048 | |
hcfmusp.relation.reference | RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012 | |
hcfmusp.relation.reference | Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874 | |
hcfmusp.relation.reference | Rocco PRM, 2003, EUR RESPIR J, V22, P20, DOI 10.1183/09031936.03.00108603 | |
hcfmusp.relation.reference | Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162 | |
hcfmusp.relation.reference | Santos CL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178207 | |
hcfmusp.relation.reference | Seitzman GD, 1998, AM J RESP CELL MOL, V18, P800, DOI 10.1165/ajrcmb.18.6.3063 | |
hcfmusp.relation.reference | Starkhammar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032110 | |
hcfmusp.relation.reference | Starling CM, 2009, RESP PHYSIOL NEUROBI, V165, P185, DOI 10.1016/j.resp.2008.11.011 | |
hcfmusp.relation.reference | Taher YA, 2010, LIBYAN J MED, V5, DOI 10.3402/ljm.v5i0.5303 | |
hcfmusp.relation.reference | Tiberio IFLC, 1997, AM J RESP CRIT CARE, V155, P1739, DOI 10.1164/ajrccm.155.5.9154886 | |
hcfmusp.relation.reference | Tulic MK, 2003, CHEST, V123, p348S, DOI 10.1378/chest.123.3_suppl.348S | |
hcfmusp.relation.reference | Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001 | |
hcfmusp.relation.reference | Venancio TM, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/1784014 | |
hcfmusp.relation.reference | Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC | |
hcfmusp.relation.reference | Wang YH, 2011, CURR ALLERGY ASTHM R, V11, P388, DOI 10.1007/s11882-011-0210-y | |
hcfmusp.relation.reference | Willis CR, 2015, AM J RESP CELL MOL, V53, P810, DOI 10.1165/rcmb.2015-0038OC | |
hcfmusp.relation.reference | Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497 | |
hcfmusp.relation.reference | Zhao Y, 2011, J ASTHMA, V48, P429, DOI 10.3109/02770903.2011.570403 | |
relation.isAuthorOfPublication | 1ab6ead0-6ef0-4c9c-885b-12adf65db05b | |
relation.isAuthorOfPublication | af6ef2e0-5bc8-4ab0-93c9-a35609d71dab | |
relation.isAuthorOfPublication | 583a4adb-71a1-42de-8a93-1325e93891fe | |
relation.isAuthorOfPublication | ae9b7d8d-df81-45ba-b1ae-bca36b86452b | |
relation.isAuthorOfPublication | af1592e7-252d-4912-b361-be7f7c064072 | |
relation.isAuthorOfPublication | 146d8d80-d4ed-4a7a-b661-fc8cd9963305 | |
relation.isAuthorOfPublication | 942afc04-b103-43d1-ba59-6c1a70778b19 | |
relation.isAuthorOfPublication | 30b65ddb-f92d-4fb7-8538-32ab9bed7597 | |
relation.isAuthorOfPublication | d95ea4d8-c3e7-4e2b-9ff0-705c31668d69 | |
relation.isAuthorOfPublication | 222fe0c7-b60e-42e9-8b03-3de63d2d1192 | |
relation.isAuthorOfPublication.latestForDiscovery | 1ab6ead0-6ef0-4c9c-885b-12adf65db05b |
Arquivos
Pacote Original
1 - 1 de 1
Carregando...
- Nome:
- art_CAMARGO_Effects_of_AntiIL17_on_Inflammation_Remodeling_and_Oxidative_2018.PDF
- Tamanho:
- 3.58 MB
- Formato:
- Adobe Portable Document Format
- Descrição:
- publishedVersion (English)